Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

ABSTRACT:

Background

Extended-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevention of relapse to opioid dependence. Data supporting its effectiveness in U.S. criminal justice populations are limited.

Methods

In this five-site, open-label, randomized trial, we compared a 24-week course of extended-release naltrexone (Vivitrol) with usual treatment, consisting of brief counseling and referrals for community treatment programs, for the prevention of opioid relapse among adult criminal justice offenders (i.e., persons involved in the U.S. criminal justice system) who had a history of opioid dependence and a preference for opioid-free rather than opioid maintenance treatments and who were abstinent

SUBMITTER: Lee JD 

PROVIDER: S-EPMC5454800 | biostudies-literature | 2016 Mar

REPOSITORIES: biostudies-literature